Overview

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

Status:
Terminated

Trial end date:
2016-10-01

Target enrollment:

Participant gender:

Summary

This will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with Clinolipid or standard of care for up to 90 days to develop Essential Fatty Acid Deficiency (EFAD). Additionally, this study design will evaluate the safety and efficacy of using Clinolipid in a pediatric population.

Phase:

Phase 4

Details

Lead Sponsor:

Baxter Healthcare Corporation

Treatments:

Soybean oil, phospholipid emulsion